Galderma Wins On 5 Patents In Generic Oracea Suit

By Cara Bayles (August 28, 2018, 5:55 PM EDT) -- Amneal Pharmaceuticals LLC's proposed generic version of Galderma Laboratories LP's flagship rosacea drug Oracea infringes five of Galderma's patents, a Delaware federal judge ruled on Monday.

Although U.S. District Judge Leonard Stark's opinion explaining the reasoning for his ruling is still under seal, his order on Monday found that Amneal's abbreviated new drug application, or ANDA, for an oral antibiotic medication meant to treat the skin condition rosacea infringes Galderma's U.S. Patent Nos. 8,206,740; 8,394,405; 8,470,364; 8,603,506; and 9,241,946.

He also found that three more patents at issue in the case — U.S. Patent Nos. 7,749,532; 7,211,267; and 7,232,572 — were...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!